192 related articles for article (PubMed ID: 37777716)
1. Active surveillance should be considered for select men with Grade Group 2 prostate cancer.
Pekala KR; Bergengren O; Eastham JA; Carlsson SV
BMC Urol; 2023 Sep; 23(1):152. PubMed ID: 37777716
[TBL] [Abstract][Full Text] [Related]
2. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
3. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
4. Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting.
Huang MM; Alam R; Gabrielson AT; Su ZT; Kassiri B; Fletcher SA; Biles MJ; Patel HD; Pavlovich CP; Schwen ZR
Eur Urol Focus; 2022 Sep; 8(5):1141-1150. PubMed ID: 34344628
[TBL] [Abstract][Full Text] [Related]
5. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
6. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
7. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
[TBL] [Abstract][Full Text] [Related]
8. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
9. Active surveillance in men with localized prostate cancer: a systematic review.
Dahabreh IJ; Chung M; Balk EM; Yu WW; Mathew P; Lau J; Ip S
Ann Intern Med; 2012 Apr; 156(8):582-90. PubMed ID: 22351515
[TBL] [Abstract][Full Text] [Related]
10. Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?
Stonier T; Tin AL; Sjoberg DD; Jibara G; Vickers AJ; Fine S; Eastham J
J Urol; 2021 Apr; 205(4):1063-1068. PubMed ID: 33216696
[TBL] [Abstract][Full Text] [Related]
11. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
Willemse PM; Davis NF; Grivas N; Zattoni F; Lardas M; Briers E; Cumberbatch MG; De Santis M; Dell'Oglio P; Donaldson JF; Fossati N; Gandaglia G; Gillessen S; Grummet JP; Henry AM; Liew M; MacLennan S; Mason MD; Moris L; Plass K; O'Hanlon S; Omar MI; Oprea-Lager DE; Pang KH; Paterson CC; Ploussard G; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; Van den Broeck T; van der Kwast TH; van der Poel HG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TBL
Eur Urol; 2022 Apr; 81(4):337-346. PubMed ID: 34980492
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
[TBL] [Abstract][Full Text] [Related]
16. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
Umbehr MH; Platz EA; Peskoe SB; Bhavsar NA; Epstein JI; Landis P; Partin AW; Carter HB
BJU Int; 2014 Apr; 113(4):561-7. PubMed ID: 23746233
[TBL] [Abstract][Full Text] [Related]
17. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
18. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
19. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
20. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]